Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
Recruiting
N/A
Interventional Study
Lobectomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 118 (estimated)
- Sponsor
- Tongji Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age range: 18 to 75 years old;
* Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
* ASA classification levels I-III;
* BMI 18 \~ 30 kg/m2。
* Voluntarily participate and sign an informed consent form.
Exclusion Criteria:
* Patients with preoperative alco…
Contacts